Compulsory prescription for the online sale of specified Ayurveda, Unani medicines: CCPA


The Central Consumer Protection Authority (CCPA) has asked e-commerce businesses not to allow the sale of Ayurvedic, Siddha and Unani medicines containing ingredients listed in Schedule E(1) of the Medicines and Medicines Rules cosmetics from 1945 until a valid prescription of a registered drug. practitioner is uploaded by the buyer on their platforms.

In a notice sent to e-commerce entities on Thursday, the CCPA said: “The Central Authority may take necessary action under the provisions of the Consumer Protection Act 2019 if, after investigation, it is found that said drugs are offered for sale by any e-commerce platform in violation of the legal framework governing the sale of such drugs for consumption.

“Now, the Central Consumer Protection Authority (CCPA) has been informed that the aforementioned category of medicines are offered for sale on e-commerce platforms without any mechanism to verify whether these medicines are purchased by a controlled user. medical supervision or not,” the notice said.

“As a result, drugs consumed without medical supervision can lead to serious health complications,” the notice states.

“It may be mentioned that in accordance with Rule 161(2) of the Medicines and Cosmetics Rules, 1945, the container of a medicine for internal use for the treatment of human ailments must, if made up of a substance specified in Schedule E(1), be conspicuously labeled with the words ‘Caution: Take under medical supervision’ in English and Hindi,” the notice said.

He said: “In view of the above, all e-commerce platforms are hereby notified that the sale or facilitation of the sale of Ayurvedic, Siddha and Unani medicines containing ingredients listed in Schedule E (1) Medicines and Cosmetics Rules, 1945 shall be done only after a valid prescription from a registered physician has been uploaded by the user or patient on the platform.

[ad_2]Source link

About Alex S. Crone

Check Also

Now is not the time for the CDC to relax opioid prescribing guidelines

[ad_1] Contact: Communications Office 850-245-4111 This month, the Centers for Disease Control and Prevention …